Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vor Biopharma ( (VOR) ) has provided an update.
On October 28, 2025, Vor Biopharma Inc. hosted a webcast to present 48-week Phase 3 clinical trial data from China for telitacicept in treating primary Sjögren’s disease. The results indicated significant improvements in disease symptoms and control, with nearly 90% of patients reporting positive outcomes. This development positions telitacicept as a potentially transformative therapy in the autoimmune disease space, enhancing Vor Biopharma’s competitive edge and offering promising implications for stakeholders in terms of market opportunities and patient treatment options.
The most recent analyst rating on (VOR) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Vor Biopharma stock, see the VOR Stock Forecast page.
Spark’s Take on VOR Stock
According to Spark, TipRanks’ AI Analyst, VOR is a Underperform.
Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.
To see Spark’s full report on VOR stock, click here.
More about Vor Biopharma
Vor Biopharma Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative therapies for autoimmune diseases. The company is particularly engaged in advancing treatments for conditions like generalized myasthenia gravis and primary Sjögren’s disease, with a market focus on leveraging dual BAFF/APRIL inhibition mechanisms.
Average Trading Volume: 341,846
Technical Sentiment Signal: Sell
Current Market Cap: $186M
For an in-depth examination of VOR stock, go to TipRanks’ Overview page.